ewopharmaSwitzerland
News | Contact | Sitemap | Disclaimer | 
news
About us  |  Services  |  Territories  |  Partners  |  
Ewopharma AG acquires Newport Pharmaceuticals Ltd.
20.10.2011

Schaffhausen, Switzerland, Oct 20, 2011 – Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Newport Pharmaceuticals Ltd., an Irish healthcare company. Newport manufactures and supplies the immunomodulator drug Isoprinosine┬« (inosine acedoben dimepranol, IAD), which is indicated for the treatment of a range of viral infections in many countries around the world.

Over the past years, Ewopharma has successfully grown the business with Isoprinosine® in Central and Eastern European markets, under license from Newport. The acquisition now gives Ewopharma full ownership and control over the product for these markets, and it also provides opportunities to Ewopharma for many new markets outside Europe.

Mr. Alain Staub, Chairman and CEO of the Ewopharma Group, commented "We have enjoyed a long standing business relationship with Newport over the past 30 years. This acquisition provides Ewopharma with the facility to develop new markets for IAD, and we are excited with this prospect. We are especially pleased with the experienced management team at Newport, headed by its General Manager Alan Johns, which will be instrumental in achieving the continued growth of the business. We expect that a number of employment opportunities will be created in connection with the acquisition."

The Irish company KoRa Healthcare, guided by its Managing Director Mr. James O’Daly, has licensed from Ewopharma / Newport the marketing and distribution rights to IAD in finished product form for the United Kingdom, the Republic of Ireland, Germany, Canada and other overseas markets. In Russia and Ukraine, Isoprinosine┬« is marketed by TEVA Pharmaceuticals under license from Ewopharma, whereas in Poland, the Czech Republic, Slovakia, Hungary, Romania and Bulgaria the product is successfully promoted by Ewopharma’s local subsidiaries. Newport, under the ownership of Ewopharma AG, will continue to supply IAD active pharmaceutical ingredient to its worldwide network of licensees and distributors.